-

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

LANCASTER, Pa.--(BUSINESS WIRE)--Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety.

Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.

Eurofins Medical Device Services North America’s GMP PFAS testing and screening solution includes:

  • Combustion Ion Chromatography (CIC) for total organic fluorine screening in solids, liquids, and gases, to provide an initial assessment of PFAS levels.
  • Process mapping and supply chain audits, to identify contamination pathways.
  • Solvent extraction and direct combustion for flexible sample formats.
  • Extractables & Leachables (E&L) testing, toxicological risk assessments, and aging studies.
  • Stability and forced degradation studies, to identify PFAS breakdown products.

Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels.

Learn more at https://www.eurofins.com/medical-device/

About Eurofins Medical Device Services

Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices—including implants, instruments, single-use and combination products, and wearables.

With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies.

Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.

Contacts

For further information:
Lisa Bamford
Medical Device Services Communications Director
Lisa.bamford@bpt.eurofinsus.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

For further information:
Lisa Bamford
Medical Device Services Communications Director
Lisa.bamford@bpt.eurofinsus.com

More News From Eurofins

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF) EUROFINS SCIENTIFIC SE – E1013 2. Identi...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 27th April to 30th April 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 27/04/2026 FR0014000MR3 35 000 62.5188 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 27/04/2026 FR0014000MR3 5 000 62.3938 CEUX EUROFINS SCIENTIFC 529900JEHFM47DY...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 23rd April to 24th April 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 40 000 61.8744 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 10 000 61.9124 CEUX EUROFINS SCIENTIFC 529900JEHFM47D...
Back to Newsroom